Utah Medical Raises Dividend as Sales Slide
Shareholders of this Utah device maker get a slightly larger payout while revenue contracts, a mix operators should weigh against peers.
Updated on Nov. 3, 2026 in Economic Indicators
Utah Medical Products raised its quarterly dividend 1.6% to $0.315 per share, declared November 3, 2026. The increase is $0.005 above the previous $0.310 rate and is payable to shareholders of record in the December 17, 2026 window for an January 5, 2027 payment, a modest signal for income-focused investors holding Utah-based medical device stocks.
Why it matters
A small, steady dividend increase arrives while the company's top line is contracting, so the payout is being funded from a shrinking revenue base. For Utah operators in medical device manufacturing, it shows how a niche maker of women's and babies' health products is choosing to reward shareholders rather than reinvest in growth at a visible scale.
The dividend rises $0.005 per share to $0.315, while third-quarter sales fell 12.1% to $8.621 million and nine-month sales declined 12.2% to $25.873 million. Diluted GAAP earnings per share rose 6.8% to $0.876 in the quarter even as revenue contracted.
The players
Utah Medical Products
A Utah-based maker of specialty disposable and reusable medical devices focused on women's and babies' health.
The details
The board raised the quarterly payout through its standard dividend declaration on November 3, 2026, moving it from $0.310 to $0.315 per share. Earnings held up better than revenue in the third quarter, with net income rising 5.9% to $2.787 million, which means the company kept more of each sales dollar as profit despite fewer sales. Over the first nine months of 2026, however, net income fell 7.4% to $8.077 million, so the quarterly gain does not yet reverse the year-to-date pattern.
Timeline
November 3, 2026: Dividend increase declared.
December 17, 2026: Record and ex-dividend date.
January 5, 2027: Dividend payment date.
Market Landscape
Utah Medical Products' nine-month 2026 sales fell 12.2% to $25.873 million, a trend the quarterly dividend raise does not reverse. The pattern places the company among smaller medical device makers that maintain shareholder payouts while revenue softens.
Operators in medical device manufacturing should note that dividend policy can remain stable even as revenue contracts, which matters when comparing peer capital-return decisions. Finance teams tracking supplier and competitor health should watch whether sales declines persist into the fourth quarter.
The takeaway
Dividend stability at a company with falling sales is a signal to read alongside revenue, not in isolation. Track the fourth-quarter filing for whether the sales decline continues against the $0.315 payout rate.
Further reading
For broader context on the measures that track business conditions across the state, see Economic Indicators in our Utah coverage.
Source note: This article includes information reported by TokenPost.
